# Hinge Bio

> Hinge Bio is a clinical-stage biotechnology company in Burlingame, California, building next-generation antibody therapeutics on its proprietary GEM-DIMER platform. The platform engineers multivalent, multispecific antibodies that bind their targets cooperatively for dramatically enhanced potency. Its lead candidate, HB2198, is a B cell-depleting agent targeting both CD19 and CD20 with enhanced natural killer cell engagement, now in Phase 1 trials for systemic lupus erythematosus and lupus nephritis. The company raised a $30M Series A led by Point72 in January 2025.

- **Founded:** 2015
- **Headquarters:** Burlingame, California, United States
- **Founders:** Daniel Capon (Co-Founder & Chief Scientific Officer), Carin Mueller Rollins (Co-Founder & Chief Operating Officer), Miriam Siekevitz (Co-Founder)
- **Team size:** ~20 employees
- **Products:** GEM-DIMER Platform, HB2198
- **Notable:** Raised $30M Series A' led by Point72 in January 2025, Received FDA IND clearance for HB2198 in SLE and lupus nephritis (October 2025), Dosed first subjects in Phase 1 trials of HB2198 (April 2026)

## Products & services

- **GEM-DIMER Platform** — A proprietary antibody-engineering platform that creates multivalent, multispecific antibody-based therapeutics designed to bind their targets cooperatively, enabling dramatically enhanced biological activity and unique functionality.
- **HB2198** — Lead clinical candidate; a novel B cell-depleting agent that simultaneously targets CD19 and CD20 with enhanced natural killer cell engagement. Demonstrated rapid, deep (>99%) B cell depletion in preclinical in vivo studies. In Phase 1 trials for systemic lupus erythematosus and lupus nephritis.

## Achievements

- Raised $30M Series A' led by Point72 in January 2025
- Received FDA IND clearance for HB2198 in SLE and lupus nephritis (October 2025)
- Dosed first subjects in Phase 1 trials of HB2198 (April 2026)
- Demonstrated >99% B cell depletion in preclinical in vivo studies
- Presented platform technology at University of Oxford and ACR Convergence 2024
- CSO Daniel Capon is co-inventor of recombinant Factor VIII for hemophilia

## Latest updates

- **2026-04** — Announced first subjects dosed in Phase 1 trials of HB2198 (one in SLE patients, one in healthy volunteers).
- **2025-10** — Received FDA IND clearance for HB2198 in systemic lupus erythematosus and lupus nephritis.
- **2025-01** — Closed $30M Series A' financing led by Point72.
- **2024-11** — Presented preclinical GEM-DIMER B cell depletion data at ACR Convergence 2024.
- **2024-08** — CSO Daniel Capon presented GEM-DIMER platform at University of Oxford, Kennedy Institute of Rheumatology.

## Links

- Website: https://hingebio.com
- LinkedIn: https://www.linkedin.com/company/hinge-bio-inc

---

Profile page: https://yespress.io/hinge-bio
Published by YesPress — https://yespress.io
Last updated: 2026-06-07